On February 24, 2022 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported that a poster will be presented at the 17th Annual HD Therapeutics Conference (hosted by CHDI Foundation) with its collaborator, Dr. Amber Southwell, on Wednesday, March 2, 2022 (Press release, Vaccinex, FEB 24, 2022, View Source [SID1234609029]). Please see Presentation details below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CHDI Conference
Date: March 2, 2022
Time: 1:00 p.m. PST/4:00 p.m. EST: Poster Section
Poster Title: Combination anti-semaphorin 4D immunotherapy and ASO-mediated total HTT lowering provide benefit beyond either individual therapy in humanized HD mice
Presenter:
Amber Southwell, Ph.D., Assistant Professor,
Burnett School of Biomedical Sciences
University of Central Florida, Orlando, FL
Add to calendar: View Source
Program Link: CHDI Meeting Information
For more information about the CHDI Foundation, please refer to the Foundation website.